1. In Vivo
  2. >>Archive

A Learning Lab For Outcomes-Based Risk-Sharing Agreements

 
• By Susan Garfield, Michael Sherman, and Roger Longman

Merck and UnitedHealth's Optum group have partnered to explore various value constructs.

The Learning Laboratory developed by Merck & Co. Inc. and UnitedHealth Group Co.'s Optum division is a multi-year collaboration. The primary goal is to learn how to design and conduct feasible, high-quality outcome-based agreements that will be acceptable to all stakeholders.

To achieve this goal, the Learning Laboratory is tackling questions such as: “How do different predictive modeling approaches compare?" and “How can contract design minimize financial and clinical risk for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By Jo Shorthouse

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By Jo Shorthouse

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By David Wild

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.